Ascelia Pharma AB (OSTO:ACE) ROC (Joel Greenblatt) %: -8,313.75% (As of Mar. 2026)


OSTO:ACE Ascelia Pharma AB OSTO:ACE
29 GF Score
Price kr0.65
! 1 Warning Sign
View Full Analysis

What is Ascelia Pharma AB ROC (Joel Greenblatt) %?

Ascelia Pharma AB OSTO:ACE -0.31% 29 ROC (Joel Greenblatt) % is -8,313.75% as of Mar. 2026. GuruFocus rates OSTO:ACE with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 1,318 Biotechnology companies, Ascelia Pharma AB ranks worse than 87.03% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Ascelia Pharma AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -8,313.75%.

The historical rank and industry rank for Ascelia Pharma AB's ROC (Joel Greenblatt) % or its related term are showing as below:

OSTO:ACE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -14168.46   Med: -12886.85   Max: -6262.73
Current: -6262.73

During the past 9 years, Ascelia Pharma AB's highest ROC (Joel Greenblatt) % was -6262.73%. The lowest was -14168.46%. And the median was -12886.85%.

OSTO:ACE's ROC (Joel Greenblatt) % is ranked worse than
87.03% of 1318 companies
in the Biotechnology industry
Industry Median: -294.23 vs OSTO:ACE: -6262.73

Ascelia Pharma AB's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -13.60% per year.


Ascelia Pharma AB  (OSTO:ACE) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Ascelia Pharma AB ROC (Joel Greenblatt) % Related Terms


Ascelia Pharma AB ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Ascelia Pharma AB's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascelia Pharma AB ROC (Joel Greenblatt) % Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only -6,798.63 -10,888.10 -12,986.61 -12,886.85 -14,168.46

Ascelia Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10,174.98 -6,320.00 -4,890.72 -5,943.40 -8,313.75

OSTO:ACE vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Ascelia Pharma AB's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascelia Pharma AB ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascelia Pharma AB's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Ascelia Pharma AB's ROC (Joel Greenblatt) % falls into.


OSTO:ACE
29GF Score
Ascelia Pharma AB OSTO:ACE
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascelia Pharma AB ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.673) - (2.042 + 0 + 9.457)
=-8.826

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.953) - (3.493 + 0 + 9.764)
=-11.304

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Ascelia Pharma AB for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-67.092/( ( (0.935 + max(-8.826, 0)) + (0.679 + max(-11.304, 0)) )/ 2 )
=-67.092/( ( 0.935 + 0.679 )/ 2 )
=-67.092/0.807
=-8,313.75 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -8,313.75% mean?
Ascelia Pharma AB (OSTO:ACE) has a ROC (Joel Greenblatt) % of -8,313.75% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Ascelia Pharma AB and its competitors. According to the industry distribution chart, Ascelia Pharma AB ranks #1147 out of 1318 companies in the Biotechnology industry, placing it in the top 87%.
Is Ascelia Pharma AB's ROC (Joel Greenblatt) % too high?
Ascelia Pharma AB's current ROC (Joel Greenblatt) % is -8,313.75%. Based on the distribution chart, Ascelia Pharma AB ranks #1147 out of 1318 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascelia Pharma AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Ascelia Pharma AB's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascelia Pharma AB ranks #1147 out of 1318 companies for ROC (Joel Greenblatt) %. This places Ascelia Pharma AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Ascelia Pharma AB and its competitors. Ascelia Pharma AB's current ROC (Joel Greenblatt) % is -8,313.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascelia Pharma AB stock overvalued right now?
Ascelia Pharma AB (OSTO:ACE) has a current ROC (Joel Greenblatt) % of -8,313.75%. The current ROC (Joel Greenblatt) % is -8,313.75%. Ascelia Pharma AB's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Ascelia Pharma AB (OSTO:ACE), the current ROC (Joel Greenblatt) % is -8,313.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascelia Pharma AB Business Description

Other Exchanges ACEs:UK
Address Hyllie Boulevard 34, Malmo, SWE, 215 32
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
29GF Score

Get the complete analysis for OSTO:ACE

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.65
Price